One patient (3%) was administered 150 mg olaparib twice per day due to severe anemia (Hb 7.8 g/dL), and 2 patients (5%) were administered 200 mg olaparib twice per day due to renal impairment (Ccr: 29.0 mL/min and 45.0 mL/min). This evidence concerns the gene GSTM1 and anemia (phenotype).